{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:14:50Z","timestamp":1774530890387,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00277-016-2745-4","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T03:30:34Z","timestamp":1467343834000},"page":"1603-1610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting"],"prefix":"10.1007","volume":"95","author":[{"given":"Blaise Felix","family":"Faye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nata","family":"Dieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macoura","family":"Gadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssou Bamar","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diariatou","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sokhna Aissatou","family":"Toure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abibatou","family":"Sall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awa Oumar","family":"Toure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tandakha Ndiaye","family":"Dieye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saliou","family":"Diop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"2745_CR1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","volume":"11","author":"S O\u2019Brien","year":"2013","unstructured":"O\u2019Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al (2013) Chronic myelogenous leukemia, version 1.2014. J Natl Compr Canc Netw 11:1327\u20131340","journal-title":"J Natl Compr Canc Netw"},{"key":"2745_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","volume":"36","author":"A Granatowicz","year":"2015","unstructured":"Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M (2015) An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med 36:197\u2013202","journal-title":"Korean J Fam Med"},{"key":"2745_CR3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/2279-042X.128145","volume":"2","author":"P Jain","year":"2013","unstructured":"Jain P, Das VN, Ranjan A, Chaudhary R, Pandey K (2013) Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or hydroxyurea. J Res Pharm Pract 2:156\u2013161","journal-title":"J Res Pharm Pract"},{"key":"2745_CR4","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","volume":"8","author":"M Kek\u00e4le","year":"2014","unstructured":"Kek\u00e4le M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence 8:1619\u20131627","journal-title":"Patient Prefer Adherence"},{"key":"2745_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"issue":"1","key":"2745_CR6","doi-asserted-by":"crossref","first-page":"e2014007","DOI":"10.4084\/mjhid.2014.007","volume":"6","author":"T Sacha","year":"2014","unstructured":"Sacha T (2014) Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis 6(1):e2014007","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2745_CR7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, Lopez-Garrido P, Montero MI et al (2010) Early intervention during Imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 95:1317\u20131324","journal-title":"Haematologica"},{"key":"2745_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","volume":"87","author":"E Faber","year":"2011","unstructured":"Faber E, Muzik J, Koza V, Deme\u010dkov\u00e1 E, Voglov\u00e1 J, Demitrovi\u010dov\u00e1 L et al (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2002 - a report from the population-based CAMELIA registry. Eur J Haematol 87:157\u2013168","journal-title":"Eur J Haematol"},{"key":"2745_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","volume":"37","author":"AM Mendizabal","year":"2013","unstructured":"Mendizabal AM, Garcia-Gonzalez P, Levine PH (2013) Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol 37:247\u2013254","journal-title":"Cancer Epidemiol"},{"key":"2745_CR10","first-page":"106","volume":"86","author":"GW Kiarie","year":"2009","unstructured":"Kiarie GW, Othieno-Abinya NA, Riyat MS (2009) The GLIVEC international patient assistance programme: the Nairobi experience. East Afr Med J 86:106\u2013107","journal-title":"East Afr Med J"},{"key":"2745_CR11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in \u201c good-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"2745_CR12","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","volume":"66","author":"JE Sokal","year":"1985","unstructured":"Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C et al (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66:1352\u20131357","journal-title":"Blood"},{"issue":"1","key":"2745_CR13","doi-asserted-by":"crossref","first-page":"2014005","DOI":"10.4084\/mjhid.2014.005","volume":"6","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G (2014) Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis 6(1):2014005","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2745_CR14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","volume":"90","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, Kantarjian HM, Cortes JE (2015) Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 90:1440\u20131454","journal-title":"Mayo Clin Proc"},{"key":"2745_CR15","doi-asserted-by":"crossref","unstructured":"Koffi KG, Nanho DC, N\u2019dathz E, Kouehion P, Dissieka R, Attia A (2010) The effect of imatinib mesylate for newly diagnosed Philadelphia chromosome-positive, chronic-phase myeloid leukemia in Sub-Saharan African patients: the experience of cote d\u2019ivoire. Adv Hematol 6p","DOI":"10.1155\/2010\/268921"},{"key":"2745_CR16","first-page":"307","volume":"22","author":"AY Segbena","year":"2012","unstructured":"Segbena AY, Kueviakoe IM, Agbetiafa K, Padaro E, Layibo Y, Dorkenoo A et al (2012) Chronic myeloid leukemia and Imatinib: experience at the Lome campus teaching hospital (Togo). Med Sante Trop 22:307\u2013311","journal-title":"Med Sante Trop"},{"key":"2745_CR17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 29:1336\u20131343","journal-title":"Leukemia"},{"key":"2745_CR18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.leukres.2015.01.011","volume":"39","author":"SE Lee","year":"2015","unstructured":"Lee SE, Choi SY, Oh YJ, Kim SH, Song HY, Yoo HL et al (2015) Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. Leuk Res 39:411\u2013418","journal-title":"Leuk Res"},{"key":"2745_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","volume":"95","author":"D Mitra","year":"2012","unstructured":"Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA (2012) Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol 95:263\u2013273","journal-title":"Int J Hematol"},{"key":"2745_CR20","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521","journal-title":"N Engl J Med"},{"key":"2745_CR21","first-page":"647","volume":"45","author":"XL Li","year":"2014","unstructured":"Li XL, Zhu HL, Liu HY, L\u00fc SJ, Zheng SP, Wu Y et al (2014) Efficacy of tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients. Sichuan Da Xue Xue Bao Yi Xue Ban 45:647\u2013651","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2745_CR22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11096-013-9876-7","volume":"36","author":"TC Chen","year":"2014","unstructured":"Chen TC, Chen LC, Huang YB, Chang CS (2014) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm 36:172\u2013181","journal-title":"Int J Clin Pharm"},{"key":"2745_CR23","first-page":"174","volume":"35","author":"SR Reis Dos","year":"2013","unstructured":"Dos Reis SR, Quixad\u00e1 AT, Nunes ST, Cid DM, de Souza JH, da Costa CM et al (2013) Adherence to treatment with Imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev Bras Hematol Hemoter 35:174\u2013179","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2745_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jnci.2015.03.004","volume":"27","author":"WA Edesa","year":"2015","unstructured":"Edesa WA, Abdel-malek RR (2015) Impact of Imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: single institution experience. J Egypt Natl Canc Inst 27:69\u201375","journal-title":"J Egypt Natl Canc Inst"},{"key":"2745_CR25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89:547\u2013556","journal-title":"Am J Hematol"},{"key":"2745_CR26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2745_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2014.12.003","volume":"29","author":"C Talati","year":"2015","unstructured":"Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M (2015) How we will treat chronic myeloid leukemia in 2016. Blood Rev 29:137\u2013142","journal-title":"Blood Rev"},{"key":"2745_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/0019-509X.134598","volume":"51","author":"NK Thota","year":"2014","unstructured":"Thota NK, Gundeti S, Linga VG, Coca P, Tara RP, Raghunadharao (2014) Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis. Indian J Cancer 51:5\u20139","journal-title":"Indian J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2745-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2745-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T05:12:39Z","timestamp":1600837959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2745-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2745-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}